Alternative Approaches to Antibiotics: Phage Therapy, Antimicrobial Peptides, and Phytotherapeutics
DOI:
https://doi.org/10.33003/fjs-2026-1013-5918Keywords:
Antibiotic resistance, Phage therapy, Antimicrobial peptides, Phytochemicals, Multidrug resistance, Alternative therapiesAbstract
Antibiotic resistance has emerged as a critical threat to global health, food security, and economic stability due to the overuse of antibiotics in human medicine and livestock production. This review examines the mechanisms of antibiotic action and resistance, clinical and environmental consequences of resistance, and evaluates current alternative strategies to conventional antibiotics. Bacteria develop resistance through enzymatic degradation, target modification, reduced membrane permeability, alternative metabolic pathways, and horizontal gene transfer. The misuse of antibiotics in animal breeding as growth promoters has further accelerated the spread of resistant and multidrug-resistant pathogens such as Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. To address this crisis, the review discusses three major alternatives: phage therapy, antimicrobial peptides (AMPs), and phytochemicals/plant extracts. Phage therapy offers highly specific bacterial lysis with minimal impact on microbiota, though challenges include narrow host range and phage resistance. AMPs exhibit broad-spectrum antimicrobial, antibiofilm, and immunomodulatory activities, with several FDA approved peptides already in clinical use, but limitations include high minimum inhibitory concentrations and potential toxicity. Plant-derived phytochemicals demonstrate antibacterial and efflux pump inhibitory effects and show synergistic potential when combined with antibiotics. The findings suggest that a multifaceted approach combining prudent antibiotic stewardship with investment in phage therapy, AMPs, and plant-based compounds is essential to mitigate resistance and ensure sustainable treatment options. Further in vivo studies and clinical trials are needed to optimize efficacy, safety, and large-scale application of these alternatives.
References
Alzoreky, N. S., & Nakahara, K. (2002). Antibacterial activity of extracts from some edible plants commonly consumed in Asia. International Journal of Food Microbiology, 80, 223–230.
Andersson, D. I., Hughes, D., & Kubicek-Sutherland, J. Z. (2016). Mechanisms and consequences of bacterial resistance to antimicrobial peptides. Drug Resistance Updates, 26, 43–57.
Antoinette, K. D., & Dieudonne, A. (2020). Etiologic profile and sensitivity pattern of germs responsible for urinary tract infection among under-five in Douala: A hospital-based study. International Journal of Infectious Diseases, 101: 358.
Arsène, M. M., Podoprigora, I. V., Davares, A. K., Razan, M., Das, M. S., & Senyagin, A. N. (2021). Antibacterial activity of grapefruit peel extracts and green-synthesized silver nanoparticles. Veterinary World, 14:(5), 1330:1341.
Baltzer, S. A., & Brown, M. H. (2011). Antimicrobial peptides: Promising alternatives to conventional antibiotics. Journal of Molecular Microbiology and Biotechnology, 20(4), 228:235.
Bruttin, A., & Brüssow, H. (2005). Human volunteers receiving Escherichia coli phage T4 orally: A safety test of phage therapy. Antimicrobial Agents and Chemotherapy, 49(7), 2874:2878.
Cairns, B. J., Timms, A. R., Jansen, V. A., Connerton, I. F., & Payne, R. J. (2009). Quantitative models of in vitro bacteriophage-host dynamics and their application to phage therapy. PLoS Pathogens, 5(1), e1000253.
Cleven, B. E., Palka-Santini, M., Gielen, J., Meembor, S., Krönke, M., & Krut, O. (2006). Identification and characterization of bacterial pathogens causing bloodstream infections by DNA microarray. Journal of Clinical Microbiology, 44(7), 2389.
Criscuolo, E., Spadini, S., Lamanna, J., Ferro, M., & Burioni, R. (2017). Bacteriophages and their immunological applications against infectious threats. Journal of Immunology Research, 2017:3780697.
Doidge, C., Ruston, A., Lovatt, F., Hudson, C., King, L., & Kaler, J. (2020). Farmers’ perceptions of preventing antibiotic resistance on sheep and beef farms: Risk, responsibility and action. Frontiers in Veterinary Science, 7: 524.
Di Pierro, F. (2025). _Phage to ESKAPE: Personalizing Therapy for MDR Infections. Host-range gaps and combination approaches.
Dublanchet, A., & Schwartz, M. (2017). Autobiographie de Félix d’Hérelle 1873:1949. Éditions Médicales Internationales.
Fankam, A., Kuete, V., Voukeng, I., & Kuiate, J. (2011). Antibacterial activities of selected Cameroonian spices and their synergistic effects with antibiotics against multidrug-resistant phenotypes. BMC Complementary and Alternative Medicine, 11(1), 104.
Faust, J. E., Yang, P. Y., & Huang, H. W. (2017). Action of antimicrobial peptides on bacterial and lipid membranes: A direct comparison. Biophysical Journal, 112(8), 1663:1672.
Geitani, R., Moubareck, C. A., Touqui, L., & Sarkis, D. K. (2019). Cationic antimicrobial peptides: Alternatives and/or adjuvants to antibiotics active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. BMC Microbiology, 19(1), 54.
Ghanavati, R. (2024). The Evolution of Phage Therapy: A Comprehensive Review. Table of challenges: host range, immune clearance, resistance, regulation.
Grandclaudon, C., Birudukota, N. S., Elgaher, W. A., Jumde, R. P., Yahiaoui, S., Arisetti, N., Hennessen, F., Huettel, S., Stadler, M., Herrmann, J., & Miethke, M. (2020). Semisynthesis and biological evaluation of amidochelocardin derivatives as broad-spectrum antibiotics. European Journal of Medicinal Chemistry, 188:112005.
Heesterbeek, D. A., Muts, R. M., van Hensbergen, V. P., de Saint Aulaire, P., Wennekes, T., Bardoel, B. W., van Sorge, N. M., & Rooijakkers, S. H. (2021). Outer membrane permeabilization by the membrane attack complex sensitizes Gram-negative bacteria to antimicrobial proteins in serum and phagocytes. PLoS Pathogens, 17(1), e1009227.
Ibrahim, O. M. S., Sarhan, S. R., & Hameed, A. A. (2015). In vivo and in vitro antibacterial activities of cranberry extract against E. coli O157:H7 in urinary tract infected rats. Advances in Animal and Veterinary Sciences, 3, 233:244.
Jenssen, H., Hamill, P., & Hancock, R. E. (2006). Peptide antimicrobial agents. Clinical Microbiology Reviews, 19(3), 491:511.
Jit, M., Ng, D. H., Luangasanatip, N., Sandmann, F., Atkins, K. E., Robotham, J. V., & Pouwels, K. B. (2020). Quantifying the economic cost of antibiotic resistance and the impact of related interventions: Rapid methodological review, conceptual framework and recommendations for future studies. BMC Medicine, 18(1), 1:14.
Jorge, A. M. S., & Eduardo, R. (2019). Environmental structure drives resistance to phages and antibiotics during phage therapy and to invading lysogens during colonisation. Scientific Reports, 9(1), 3149.
Jun, K. (2017). Phage as a therapeutic agent. Medium. https://thryve.medium.com/phage-as-a-therapeutic-agent-ed4c466302e5
Kobras, C. M., Piepenbreier, H., Emenegger, J., Sim, A., Fritz, G., & Gebhard, S. (2020). BceAB-type antibiotic resistance transporters appear to act by target protection of cell wall synthesis, 64(3), e02241:19.
Koskella, B., & Meaden, S. (2013). Understanding bacteriophage specificity in natural microbial communities. Viruses, 5, 806:823.
Lei, J., Sun, L., Huang, S., Zhu, C., Li, P., He, J., Mackey, V., Coy, D. H., & He, Q. (2019). The antimicrobial peptides and their potential clinical applications. American Journal of Translational Research, 11(7), 3919:3931.
Li, W., Tailhades, J., O’Brien-Simpson, N. M., Separovic, F., Otvos, L., Hossain, M. A., & Wade, J. D. (2014). Proline-rich antimicrobial peptides: Potential therapeutics against antibiotic resistant bacteria. Amino Acids, 46(10), 2287:2294.
Lima, T., Domingues, S., & Da Silva, G. J. (2020). Manure as a potential hotspot for antibiotic resistance dissemination by horizontal gene transfer events. Veterinary Sciences, 7(3), 110.
Mahlapuu, M., Håkansson, J., Ringstad, L., & Björn, C. (2016). Antimicrobial peptides: An emerging category of therapeutic agents. Frontiers in Cellular and Infection Microbiology, 6, 194.
Mbarga, M. J. A., Andreevna, S. L., & Viktorovna, P. I. (2020). Evaluation of apparent microflora and study of antibiotic resistance of coliforms isolated from the shells of poultry eggs in Moscow Russia. Journal of Advances in Microbiology, 20(4), 70:77.
Mbarga, M. J. A., Podoprigora, I. V., Anyutoulou, K. L. D., Ngah, E., & Senyagin, A. N. (2021). Urinary tract infections (UTIs): Virulence factors, resistance to antibiotics and management of uropathogenic bacteria with medicinal plants. A review. Journal of Applied Pharmaceutical Science, 11(7), 001:012.
Mireille, A., Pascale, B., Charlotte, B., Laurent, D., Nicolas, D., Rémy, F., Sylvain, G., Claire, L. H., Marie-Agnès, P., Eduardo, R., & Clara, T. B. (2020). Les applications antibactériennes des bactériophages. Virologie, 24(1), 23:36.
Morel, C. M., Lindahl, O., Harbarth, S., de Kraker, M. E., Edwards, S., & Hollis, A. (2020). Industry incentives and antibiotic resistance: An introduction to the antibiotic susceptibility bonus. Journal of Antibiotics, 73(7), 421:428.
Międzybrodzki, R., Borysowski, J., Weber-Dąbrowska, B., Fortuna, W., Letkiewicz, S., Szufnarowski, K., Pawełczyk, Z., Rogóż, P., Kłak, M., Wojtasik, E., & Górski, A. (2012). Clinical aspects of phage therapy. Advances in Virus Research, 83, 73:121.
Nascimento, G. G. F., Locatelli, J., Freitas, P. C., & Silva, G. L. (2000). Antibacterial activity of plant extracts and phytochemicals on antibiotic-resistant bacteria. Brazilian Journal of Microbiology, 31, 247:256.
Nobrega, F. L., Costa, A. R., Kluskens, L. D., & Azeredo, J. (2015). Revisiting phage therapy: New applications for old resources. Trends in Microbiology, 23, 185:191.
Palma, E., Tilocca, B., & Roncada, P. (2020). Antimicrobial resistance in veterinary medicine: An overview. International Journal of Molecular Sciences, 21(6), 1914.
Payne, R. J., & Jansen, V. A. (2001). Understanding bacteriophage therapy as a density-dependent kinetic process. Journal of Theoretical Biology, 208(1), 37:48.
Pollock, J., Low, A. S., McHugh, R. E., Muwonge, A., Stevens, M. P., Corbishley, A., & Gally, D. L. (2020). Alternatives to antibiotics in a one health context and the role genomics can play in reducing antimicrobial use. Clinical Microbiology and Infection, 26(12), 1617:1621.
Prasanth, M., Ramesh, N., & Bruno, S. L. (2018). The therapeutic potential of bacteriophages targeting gram-negative bacteria using. Galleria mellonella infection model. BMC Microbiology, 18: 97.
Rabello, R. F., Bonelli, R. R., Penna, B. A., Albuquerque, J. P., Souza, R. M., & Cerqueira, A. M. (2020). Antimicrobial resistance in farm animals in Brazil: An updated overview. Animals, 10(4), 552.
Raheem, N., & Straus, S. K. (2019). Mechanisms of action for antimicrobial peptides with antibacterial and antibiofilm functions. Frontiers in Microbiology, 10, 2866.
Reis, A. C., Kolvenbach, B. A., Nunes, O. C., & Corvini, P. F. (2020). Biodegradation of antibiotics: The new resistance determinantsPart I. New Biotechnology, 54, 34:51.
Rončević, T., Puizina, J., & Tossi, A. (2019). Antimicrobial peptides as anti-infective agents in pre-post-antibiotic era? International Journal of Molecular Sciences, 20(22), 5713.
Sadhana, S. S., Ram, N. A., Rajesh, K., & Shilpa, D. K. (2018). Reversal of antibiotic resistance by phage resistant Pseudomonas aeruginosa PA01. Journal of Biosciences and Bioengineering, 6(1), 11:15.
Schaenzer, A. J., & Wright, G. D. (2020). Antibiotic resistance by enzymatic modification of antibiotic targets. Trends in Molecular Medicine, 26(8), 768:782.
Shriram, V., Khare, T., Bhagwat, R., Shukla, R., & Kumar, V. (2018). Inhibiting bacterial drug efflux pumps via phyto-therapeutics to combat threatening antimicrobial resistance. Frontiers in Microbiology, 9, 2990.
Skurnik, M., & Strauch, E. (2006). Phage therapy: Facts and fiction. International Journal of Medical Microbiology, 296(1), 5:14.
Solnier, J., Martin, L., Bhakta, S., & Bucar, F. (2020). Flavonoids as novel efflux pump inhibitors and antimicrobials against both environmental and pathogenic intracellular mycobacterial species. Molecules, 25, 734.
Stokes, J. M., Lopatkin, A. J., Lobritz, M. A., & Collins, J. J. (2019). Bacterial metabolism and antibiotic efficacy. Cell Metabolism, 30(2), 251:259.
Tran, H. T., Solnier, J., Pferschy-Wenzig, E. M., Kunert, O., Martin, L., Bhakta, S., Huynh, L., Le, T. M., Bauer, R., & Bucar, F. (2020). Antimicrobial and efflux pump inhibitory activity of carvotacetones from Sphaeranthus africanus against mycobacteria. Antibiotics, 9(7), 390.
Ullah, N., Parveen, A., Bano, R., Zulfiqar, I., Maryam, M., Jabeen, S., Liaqat, A., & Ahmad, S. (2016). In vitro and in vivo protocols of antimicrobial bioassay of medicinal herbal extracts: A review. Asian Pacific Journal of Tropical Disease, 6, 660:667.
Van Belleghem, J. D., Dabrowska, K., Vanee, M., Barr, J. J., & Bollyky, P. L. (2018). Interactions between bacteriophage, bacteria and the mammalian immune system. Viruses, 11(1), 10.
Vasilchenko, A. S., & Rogozhin, E. A. (2019). Sub-inhibitory effects of antimicrobial peptides. Frontiers in Microbiology, 10, 1160.
Ventola, C. L. (2015). The antibiotic resistance crisis: Part 1: Causes and threats. Pharmacy and Therapeutics, 40(4), 277:283.
World Health Organization. (2019, April 29). New report calls for urgent action to avert antimicrobial resistance crisis. https://www.who.int/news/item/29-04-2019-new-report-calls-for-urgent-action-to-avert-antimicrobial-resistance-crisis
World Health Organization. (2020). Antibiotic resistance. https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance
WHO. (2024). Antibiotic resistance surges globally, UN health agency warns. 2024. 1.27M deaths directly from AMR in 2019; 40% rise 2018-2023.
WHO. (2023). Antibiotic resistance surges globally, UN health agency warns. (1.27M deaths directly from AMR in 2019.
WHO. 2018). Antibiotic resistance surges globally, UN health agency warns. 1.27M deaths directly from AMR in 2019
WHO. (2023). Product & Delivery Research: AMR a significant global health threat. Pipeline and access challenges.
Xu, L., Zhou, Z., Zhu, L., Han, Y., Lin, Z., Feng, W., Liu, Y., Shuai, X., & Chen, H. (2020). Antibiotic resistance genes and microcystins in a drinking water treatment plant. Environmental Pollution, 258, 113718.
Zhou, J., Liu, Y., Shen, T., Chen, L., Zhang, C., Cai, K., Liao, C., & Wang, C. (2019). Antimicrobial activity of the antibacterial peptide PMAP-36 and its analogues. Microbial Pathogenesis, 136, 103712.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2026 Haruna Abdullahi, Haliru Ahmad Kabiru, Habila Mamman Paul, Satvil Dalis James, Taiye Salawudeen Muibat, Uche Samuel Ndidi
This work is licensed under a Creative Commons Attribution 4.0 International License.
